Pharma BD Deal Intelligence
A tax-inversion deal that worked as financial engineering—cutting Actavis's effective tax rate from the high-30s% to ~17%—but whose acquired Warner Chilcott brand portfolio (Actonel, Asacol HD, Estrace, Lo Loestrin Fe) was quickly absorbed and diluted as the $8.5B platform enabled Actavis's much larger follow-on Forest Labs and $70.5B Allergan acquisitions, after which the Actavis name itself disappeared into Allergan plc.
Susquehanna's Andrew Finkelstein said the deal would give Actavis 'an earnings jolt' starting next year; Morningstar's Michael Waterhouse: 'we're probably not…
Actavis is buying Warner Chilcott in an all-stock deal valued at about $8.5 billion that would create the third-biggest specialty pharmaceutical company in the…
FTC consent order required divestiture of overlapping products including oral contraceptive Lo Loestrin Fe generic equivalents to remedy competitive concerns —…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Actavis acquired Warner Chilcott in a stock-for-stock transaction valued at approximately $8.5 billion, creating Actavis plc, an Ireland-domiciled specialty pharmaceutical company with roughly $11 billion in pro forma revenue. The transaction established the Irish tax-inversion structure later used for the Forest Laboratories acquisition.
Assessment window: 5yr post-close.
The Warner Chilcott portfolio spanned ulcerative colitis (Asacol/Delzicol mesalamine), women's health (Lo Loestrin Fe, Estrace, Femring, Atelvia), and dermatology (Doryx) — branded specialty assets with mixed exclusivity profiles and pending generic erosion (Actonel/risedronate already losing share). Several products are chronic-disease maintenance therapies in markets where generics had not fully displaced branded use.
Pre-deal, Actavis was a top-3 US generics house with limited branded specialty footprint (~7% of revenue). Warner Chilcott — a 2004 PE carve-out of P&G Pharma led by CCMP, Bain, JPM Partners and others — was a mid-cap specialty Rx company with concentrated franchises in oral contraception (Lo Loestrin Fe, the largest US OC brand by 2013), oral mesalamine for UC (Asacol, ~$800M/year, facing 2013 patent expiry triggering the Delzicol switch), and bone health (Actonel, declining post-LOE). Competitors included Bayer's Yaz/Yasmin franchise in OC, Takeda/Shire (Lialda) in UC, and Allergan/Sanofi-Genzyme in dermatology and bone respectively. Analyst sentiment was split: Susquehanna's Andrew Finkelstein called the deal 'an earnings jolt' for Actavis, while Morningstar's Michael Waterhouse warned 'I would say we're probably not as enthusiastic as the market has been... both companies were a bit overvalued'. Strategically, the deal's lasting value was the Ireland-domiciled Actavis plc shell — which Bin notes — became the platform for the 2014 Forest Labs and 2015 Allergan mega-mergers.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Actavis plc / Warner Chilcott plc (this deal) | 2013 | $8.5B | 63 |
| Actavis plc / Forest Laboratories, Inc. | 2014 | $25.0B | 75 |
| Actavis plc / Allergan plc | 2014 | $70.5B | 61 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
← Browse all deals · How we score deals
More: 2013 deals · Actavis plc deals · Dermatology deals